Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435901 · ClinicalTrials.gov registry record · Phase 1
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
A Phase 1 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02435901 is a Phase 1 study that has completed, run by Northwell Health. The registered enrollment target is 29 participants.
The verdict
NCT02435901, a Phase 1 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will evaluate the use of reduced intensity conditioning regimen in patients with high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard immunosuppressive medications, followed by a routine stem cell transplant in order to assess whether or not it is as effective as myeloablative high dose chemotherapy and transplant.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Cyclosporine
- DRUG Mycophenolate mofetil
- DRUG alemtuzumab (Campath IH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-12 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435901
The ClinicalTrials.gov registry entry for NCT02435901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02435901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435901 about?
NCT02435901 is a clinical study titled "HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity". This study will evaluate the use of reduced intensity conditioning regimen in patients with high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard immunosuppressive medications, followed by a routine stem cell transplant in order to assess whether or not it is as...
What is the current status of trial NCT02435901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-12. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02435901?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Cyclosporine (DRUG), Mycophenolate mofetil (DRUG), alemtuzumab (Campath IH) (DRUG).
Who is sponsoring clinical trial NCT02435901?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.